AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended

Aeon Biopharma

12/08/2026 21:24

Overview
U.S. biopharmaceutical firm's Q2 net loss narrowed to $1.2 mln, loss per share $0.02
Company completed $15.3 mln financing, extending cash runway into Q1 2027
After quarter-end, company restored compliance with NYSE American listing requirements

Outlook
Company expects FDA feedback on ABP-450 development in the second half of 2026
Company expects cash runway into Q1 2027, including July financing proceeds

Result Drivers
REGULATORY PROGRESS - Co highlighted continued advancement of ABP-450 biosimilar program and receipt of FDA feedback supporting analytical development approach
SCIENTIFIC PRESENTATIONS - Co presented data at medical conferences supporting analytical similarity between ABP-450 and onabotulinumtoxinA
WARRANT FAIR VALUE GAIN - Q2 net loss narrowed as co recorded a $4.9 mln gain from change in fair value of warrants

Company press release: ID:nGNX5Q2cxV

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.02
 
Q2 Net Loss
 
$1.16 mln
 
Q2 EBIT
 
-$5.92 mln
 
Q2 Pretax Loss
 
$1.16 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aeon Biopharma Inc is $5.00, about 1,731.5% above its August 11 closing price of $0.27

Reuters Recommended Reads
Aug 12 - Annexon Biosciences Q2 net loss widens, cash runway extended
Aug 12 - Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows
Aug 12 - CNS Pharmaceuticals Q2 net loss widens, cash rises after financing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)